Tamoxifen has been the major adjuvant therapy for ER+ breast cancer, but one-third of early-stage patients treated with tamoxifen after surgery for five years will experience a relapse of cancer within fifteen years [3, 4]. The gene discussed is ESR1; the disease is breast carcinoma.